Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Intravenous ketamine and immersive virtual reality to treat depression
EF 2023-24
Résumé
Over the course of their lifetimes, 9.9% of Canadians develop Major Depressive Disorder (MDD). In any given year, approximately 1 in 25 Canadians experience a depressive episode, leading 6.6% of those who experience active symptoms of depression to attempt suicide. Canadians with depression incur healthcare expenses that are over three times higher than those of their non-depressed counterparts. Nevertheless, approximately one-third of people with MDD do not achieve adequate relief with existing antidepressant medications and psychotherapy. Therefore, there is a pressing need to evaluate novel treatments, especially with rapid-onset of effects, to decrease the significant morbidity and mortality associated with this disorder.
Over the last decade, ketamine, a common anesthetic drug, has been identified as a rapid and effective antidepressant in those with treatment-resistant depression. A transient effect of ketamine is dissociative symptoms, which can include an “out-of-body” experience, which in some cases is associated with the overall therapeutic response of this treatment. A similar sensation of being separated from reality can also be created using virtual reality (VR), another emerging treatment modality for MDD, in which an electronic headset immerses users in a computer-generated, three-dimensional world. Ketamine and VR are both promising new treatments for depression.
In this pilot study, patients with depression use VR while receiving intravenous (IV) ketamine. We will test the tolerability, usability, and effectiveness of this combination to inform the feasibility of future larger clinical trials. We expect that ketamine plus VR will be more effective than either alone and, if so, that together they can improve treatment for many people living with MDD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506328
Name
Syed Omer Ahmed
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Intravenous ketamine and immersive virtual reality to treat depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Ketamine; Treatment-Resistant Depression; Virtual Reality
Abstract
Over the course of their lifetimes, 9.9% of Canadians develop Major Depressive Disorder (MDD). In any given year, approximately 1 in 25 Canadians experience a depressive episode, leading 6.6% of those who experience active symptoms of depression to attempt suicide. Canadians with depression incur healthcare expenses that are over three times higher than those of their non-depressed counterparts. Nevertheless, approximately one-third of people with MDD do not achieve adequate relief with existing antidepressant medications and psychotherapy. Therefore, there is a pressing need to evaluate novel treatments, especially with rapid-onset of effects, to decrease the significant morbidity and mortality associated with this disorder.
Over the last decade, ketamine, a common anesthetic drug, has been identified as a rapid and effective antidepressant in those with treatment-resistant depression. A transient effect of ketamine is dissociative symptoms, which can include an “out-of-body” experience, which in some cases is associated with the overall therapeutic response of this treatment. A similar sensation of being separated from reality can also be created using virtual reality (VR), another emerging treatment modality for MDD, in which an electronic headset immerses users in a computer-generated, three-dimensional world. Ketamine and VR are both promising new treatments for depression.
In this pilot study, patients with depression use VR while receiving intravenous (IV) ketamine. We will test the tolerability, usability, and effectiveness of this combination to inform the feasibility of future larger clinical trials. We expect that ketamine plus VR will be more effective than either alone and, if so, that together they can improve treatment for many people living with MDD.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Syed, Omer Ahmed
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~